January 17, 2017Open Access
Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis
Key Result
Atrial fibrillation in patients with hypertrophic cardiomyopathy was associated with higher mortality compared to those without atrial fibrillation (30.8% vs 18.2%; OR 2.49, 95% CI 1.85-3.35).
Study Design
Type
Meta-Analysis (n=6,858)
Structured PICO
Does the presence of atrial fibrillation increase mortality in patients with hypertrophic cardiomyopathy?
P
Population
6,858 patients with hypertrophic cardiomyopathy, 1,314 (19%) of whom had a history of atrial fibrillation, followed for a mean of 4 to 8 years.
E
Exposure
Presence of atrial fibrillation (AF)
C
Comparator
Absence of atrial fibrillation (HCM patients without AF)
O
Outcome
Composite of cardiac mortality and/or all-cause mortalityhard clinical
The presence of atrial fibrillation in patients with hypertrophic cardiomyopathy is associated with a significantly increased risk of all-cause and cardiac mortality.
Main Result
Odds Ratio: 2.49 (95% CI 1.85–3.35)
Absolute Event Rate: 30.8% vs 18.2%
Abstract
Background: Atrial fibrillation (AF) is a frequent occurrence in patients with hypertrophic cardiomyopathy (HCM). It is associated with worsening symptoms, cardiovascular events, and mortality. We conducted a meta-analysis of studies reporting on mortality in patient with HCM and AF. Methods: We searched PubMed, Medline, Embase, Ovid and Cochrane for studies which reported cardiovascular events and mortality in patients with HCM and AF. Outcome was a composite of cardiac mortality and/or all-cause mortality. Mantel Haenszel odds ratio (OR) or hazard ratio (HR) were calculated using random-effects meta-analysis for the prespecified outcome. Heterogeneity was assessed using I 2 statistics. Results: Six studies met the inclusion criteria. There were 6,858 patients; 1,314 (19%) had history of AF. During a mean follow up that ranged between 4 and 8 years, 405 (30.8%) patients with AF died as compared to 1,011 (18.2%) patients without AF (OR =2.49, 95% CI: 1.85–3.35, P 2 =57%). Results persisted with inclusion of studies only reporting specifically on cardiac mortality (OR =2.80, 95% CI: 1.79–4.39, P 2 =56%). Also, the mortality difference persisted after exclusion of deaths secondary to stroke in both groups (2 studies, 1,398 patients, OR =2.57, 95% CI: 1.57–4.20, P=0.0002, I 2 =31%). In three studies (5,857 patients); the presence of AF was associated with a pooled HR of 1.66 (95% CI: 1.29–2.13, P 2 =41%). Conclusion: Patients with HCM who develop AF have higher risk of mortality and cardiac deaths as compared to HCM patients without AF.